Research Paper Volume 13, Issue 19 pp 22963—22984

RUNX2 and LAMC2: promising pancreatic cancer biomarkers identified by an integrative data mining of pancreatic adenocarcinoma tissues

The clinical application value of RUNX2 and LAMC2 expression. (A) Expression levels of RUNX2 and LAMC2 in pancreatic cancer (PC) patients of different clinical stages. (B) Expression levels of RUNX2 and LAMC2 in different sex groups of PC patients. (C) Expression levels of RUNX2 and LAMC2 in different age groups of PC patients. (D) Expression levels of RUNX2 and LAMC2 in different tumor subtypes of PC patients. (E) Expression levels of RUNX2 and LAMC2in different tumor status groups of PC patients. (F) Survival analysis of combined RUNX2 and LAMC2 in TCGA PAAD cohort.

Figure 6. The clinical application value of RUNX2 and LAMC2 expression. (A) Expression levels of RUNX2 and LAMC2 in pancreatic cancer (PC) patients of different clinical stages. (B) Expression levels of RUNX2 and LAMC2 in different sex groups of PC patients. (C) Expression levels of RUNX2 and LAMC2 in different age groups of PC patients. (D) Expression levels of RUNX2 and LAMC2 in different tumor subtypes of PC patients. (E) Expression levels of RUNX2 and LAMC2in different tumor status groups of PC patients. (F) Survival analysis of combined RUNX2 and LAMC2 in TCGA PAAD cohort.